- Medicine (St Vincent's) - Research Publications
Medicine (St Vincent's) - Research Publications
Permanent URI for this collection
102 results
Filters
Reset filtersSettings
Statistics
Citations
Search Results
Now showing
1 - 10 of 102
-
ItemUpadacitinib treatment in patients with moderate to severe atopic dermatitis: A retrospective single-centre Australian review of 14 patients post phase 3 clinical trialBennett, M ; Sinclair, RD ; Eisman, S (WILEY, 2023-02)Recent phase 2b and phase 3 clinical trials support the safety and efficacy of the selective Janus kinase (JAK)-1 inhibitor upadacitinib (UPA) in the treatment of moderate to severe atopic dermatitis (AD). However, to date, there is little experience with UPA therapy for AD in Australia. We report findings from a retrospective study to better understand the therapeutic response and side effects noted in a single-centre Australian cohort.
-
ItemRegrowth of hair in congenital triangular alopecia induced by sublingual minoxidilClarysse, KLJ ; Sinclair, R (WILEY, 2023-02)
-
ItemThe alopecia areata donut sign. Evidence of synchronous hair growth in adult humansAsfour, L ; Jones, LN ; Sinclair, RD (WILEY, 2023-04)
-
ItemNo Preview AvailableEffect of gender-affirming hormone therapy on hair growth: a systematic review of the literatureTang, GT ; Zwickl, S ; Sinclair, R ; Zajac, JD ; Cheung, AS (OXFORD UNIV PRESS, 2023-09-19)Gender-affirming hormone therapy (GAHT) leads to changes in body composition, secondary sex characteristics and in the distribution and pattern of hair growth. Transgender individuals undergoing GAHT may experience altered hair growth patterns that may be affirming and desirable, or undesirable with a subsequent impact on their quality of life. Given increasing numbers of transgender individuals commencing GAHT worldwide and the clinical relevance of the impact of GAHT on hair growth, we systematically reviewed the existing literature on the impact of GAHT on hair changes and androgenic alopecia (AGA). The majority of studies used grading schemes or subjective measures of hair changes based on patient or investigator's examination. Very few studies used objective quantitative measures of hair parameters but demonstrated statistically significant changes in hair growth length, diameter and density. Feminizing GAHT with estradiol and/or antiandrogens in transgender women may reduce facial and body hair growth and also can improve AGA. Masculinizing GAHT with testosterone in transgender men may increase facial and body hair growth as well as induce or accelerate AGA. The impact of GAHT on hair growth may not align with a transgender person's hair growth goals and specific treatment for AGA and/or hirsutism may be sought. Further research on how GAHT affects hair growth is required.
-
ItemClinical features and treatment outcomes of frontal fibrosing alopecia in menMoussa, A ; Bennett, M ; Bhoyrul, B ; Kazmi, A ; Asfour, L ; Sinclair, RD (WILEY, 2022-10)
-
ItemPhase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisMurrell, DF ; Patsatsi, A ; Stavropoulos, P ; Baum, S ; Zeeli, T ; Kern, JS ; Sinclair, R ; Neale, A ; Arora, P ; Sugerman, PB ; Shi, G ; Werth, VP ; Caux, F ; Joly, P (WILEY, 2022-10)
-
ItemConcurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinibAsfour, L ; Getsos Colla, T ; Moussa, A ; Sinclair, RD (WILEY, 2022-11)
-
ItemTreatment of generalized granuloma annulare with tildrakizumabAwad, A ; Nirenberg, A ; Sinclair, R (WILEY, 2022-08)
-
ItemSuccessful treatment of chronic severe alopecia areata with abrocitinibBennett, M ; Moussa, A ; Sinclair, R (WILEY, 2022-05)
-
ItemTreatment of dissecting cellulitis of the scalp with TildrakizumabAwad, A ; Sinclair, R (WILEY, 2022-08)